Open AccessIntranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains
Author(s) -
Chunhong Dong,
Ye Wang,
Gilbert X. Gonzalez,
Yao Ma,
Yufeng Song,
Shelly Wang,
SangMoo Kang,
Richard W. Compans,
BaoZhong Wang
Publication year - 2021
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2024998118
Subject(s) - heterologous , immune system , nasal administration , vaccination , immunization , virology , influenza a virus , virus , microbiology and biotechnology , biology , antigen , influenza vaccine , immunology , gene , biochemistry
Significance A noninvasive intranasal (i.n.) influenza vaccine can induce mucosal immune responses in respiratory tracts, preventing infection at the portal of virus entry. However, the absence of appropriate mucosal adjuvants at present hinders the development of such a vaccine. Here, we developed polyethyleneimine-functionalized two-dimensional graphene oxide nanoparticles (GP) that showed high antigen-loading capacities and superior immunoenhancing properties. Robust and broadly reactive immune responses were induced with i.n. immunization with GP-HA nanoparticles, conferring protection against homologous and heterologous viruses. With versatility and flexibility, GP nanoparticles can be easily adapted for constructing mucosal vaccines of different respiratory pathogens.